A dispute has arisen in the Risperdal litigation in Philadelphia over whether new plaintiffs in the mass tort should have to include prescription records and documentation of a Risperdal-related injury in their plaintiff fact sheets.
The defendant in the case, Janssen Pharmaceuticals, raised the issue, arguing it will help the courts weed out nonmeritorious claims, but plaintiffs have countered the requirement would create a “pseudo-summary judgment procedure” that would bypass the usual process.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
